Equity awards: C4 Therapeutics (NASDAQ: CCCC) CBO granted 200,000 RSUs

Rhea-AI Filing Summary

C4 Therapeutics Chief Business Officer Scott N. Boyle reported equity compensation activity in C4 Therapeutics, Inc. common stock. On February 13, 2026, he received a grant of 200,000 restricted stock units (RSUs), with 100,000 RSUs vesting in three equal annual installments starting February 13, 2027, and 100,000 RSUs vesting in full on February 13, 2029, subject to performance milestones. On February 13 and 14, 2026, previously granted RSUs vested, resulting in the acquisition of 25,950 shares of common stock through derivative exercises, while 9,004 shares were withheld by the company at $1.89 per share to satisfy tax obligations, which the filing states does not represent an open market sale. After these transactions, Boyle directly owned 298,801 shares of common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boyle Scott N

(Last) (First) (Middle)

C/O C4 THERAPEUTICS, INC.

490 ARSENAL WAY #120

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		A		200,000(1)	A	$0	307,805	D
Common Stock	02/13/2026		M(2)	V	5,000	A	$0	307,805	D
Common Stock	02/13/2026		F(3)		1,735	D	$1.89	306,070	D
Common Stock	02/14/2026		M(2)	V	20,950	A	$0	306,070	D
Common Stock	02/14/2026		F(2)		7,269	D	$1.89	298,801	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 100,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 100,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.

2. Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 14, 2024 and February 18, 2025.

3. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.

Remarks:

	/s/ Shagha Russell, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did C4 Therapeutics (CCCC) report about Scott N. Boyle’s new RSU grant?

C4 Therapeutics granted Scott N. Boyle 200,000 RSUs of common stock. Half vest in three equal annual installments from February 13, 2027, and the remaining 100,000 RSUs vest fully on February 13, 2029, subject to specified performance milestones.

How many C4 Therapeutics (CCCC) shares did Scott N. Boyle acquire through vesting and exercises?

Scott N. Boyle acquired 25,950 shares of C4 Therapeutics common stock through vesting and exercise of previously granted RSUs. These shares came from derivative exercises reported on February 13 and February 14, 2026, at a stated exercise price of $0.00 per share.

Why were some C4 Therapeutics (CCCC) shares disposed of in Scott N. Boyle’s Form 4?

The Form 4 shows dispositions of 9,004 shares of C4 Therapeutics common stock. Footnotes explain these shares were withheld by the company at $1.89 per share solely to satisfy tax withholding obligations upon RSU vesting, not as open market sales.

What is Scott N. Boyle’s resulting ownership in C4 Therapeutics (CCCC) after these transactions?

After the reported RSU grant, vesting, exercises, and tax-withholding share reductions, Scott N. Boyle directly owns 298,801 shares of C4 Therapeutics common stock. The filing characterizes all reported holdings as directly owned, with no indirect ownership footnotes disclosed.

How do the new RSUs for Scott N. Boyle at C4 Therapeutics (CCCC) vest over time?

Of the 200,000 RSUs granted, 100,000 vest in three equal annual installments starting on February 13, 2027. The remaining 100,000 RSUs vest in full on February 13, 2029, contingent on achieving certain performance milestones described in the grant terms.

Were the C4 Therapeutics (CCCC) tax-related share dispositions by Scott N. Boyle open market sales?

The Form 4 states the tax-related dispositions were shares withheld by C4 Therapeutics to satisfy tax obligations. Footnotes clarify these do not represent open market sales by Scott N. Boyle but an administrative withholding mechanism.